Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ibrutinib has significantly improved the outcome of patients with relapsed chronic lymphocytic leukemia (CLL). Recent reports attribute ibrutinib resistance to acquired mutations in Bruton agammaglobulinemia tyrosine kinase (BTK), the target of ibrutinib, as well as the immediate downstream effector...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Liu, Ta-Ming, Woyach, Jennifer A., Zhong, Yiming, Lozanski, Arletta, Lozanski, Gerard, Dong, Shuai, Strattan, Ethan, Lehman, Amy, Zhang, Xiaoli, Jones, Jeffrey A., Flynn, Joseph, Andritsos, Leslie A., Maddocks, Kami, Jaglowski, Samantha M., Blum, Kristie A., Byrd, John C., Dubovsky, Jason A., Johnson, Amy J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2015
Schlagworte:
Lymphoid Neoplasia
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492196/
https://ncbi.nlm.nih.gov/pubmed/25972157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-626846
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge